Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD

Drick, Nora; Fuge, Jan; Seeliger, Benjamin; Speth, Milan; Vogel‐Claussen, Jens; Welte, Tobias; Suhling, Hendrik

doi:10.1183/23120541.00207-2022

Cited by 11 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, although mepolizumab has exhibited favorable long-term safety in clinical studies (Gleich et al, 2021;Maspero et al, 2022), long-term safety data beyond 1 year in realworld settings are lacking. Moreover, mepolizumab has been approved recently for severe eosinophilic asthma in patients aged 6 years and older in many countries (Drick et al, 2022). However, there is limited data available to evaluate the safety of mepolizumab in the pediatric population.…”

Section: Discussionmentioning

confidence: 99%

Anti-inflammatory drug development focusing on immune mediated diseases

Monteiro,

Prasad,

Bhatti

et al. 2024

Frontiers Research Topics

View full text Add to dashboard Cite

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers journal seriesThe Frontiers journal series is a multi-tier and interdisciplinary set of openaccess, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers journal series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to qualityEach Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public -and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics?Frontiers Research Topics are very popular trademarks of the Frontiers journals series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-inflammatory drug development focusing on immune mediated diseases

Monteiro,

Prasad,

Bhatti

et al. 2024

Frontiers Research Topics

View full text Add to dashboard Cite

show abstract

“…In COPD, the role of IL-5 and its potential targeting remains a conundrum. Indeed, some studies advocate for the use of anti-IL-5/IL-5R treatment [35][36][37] based on benefits on exacerbations while others call for more research to identify patients that would benefit from IL-5 targeting [38][39][40].…”

Section: Discussion and Future Directionsmentioning

confidence: 99%

Elastin-derived peptides favor type 2 innate lymphoid cells in COPD

Lahire,

Fichel,

Rubaszewski

et al. 2023

Preprint

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a condition characterized by chronic airway inflammation and obstruction, primarily caused by tobacco smoking. Although the involvement of immune cells in COPD pathogenesis is well established, the contribution of innate lymphoid cells (ILC) remains poorly understood. ILC are a type of innate immune cells that participate in tissue remodeling processes, but their specific role in COPD has not been fully elucidated. During COPD, the breakdown of pulmonary elastin generates elastin peptides that elicit biological activities on immune cells. This study aimed to investigate the presence of ILC in COPD patients and examine the impact of elastin peptides on their functionality. Our findings revealed an elevated proportion of ILC2 in the peripheral blood of COPD patients, and a general activation of ILC as indicated by an increase in their cytokine secretion capacity. Notably, our study demonstrated that serum from COPD patients promotes ILC2 phenotype, likely due to the elevated concentration of IL-5, a cytokine known to favor ILC2 activation. Furthermore, we uncovered that this increase in IL-5 secretion is partially attributed to its secretion by macrophages upon stimulation by elastin peptides, suggesting an indirect role of elastin peptides on ILC in COPD. These findings shed light on the involvement of ILC in COPD and provide insights into the potential interplay between elastin breakdown, immune cells, and disease progression. Further understanding of the mechanisms underlying ILC activation and their interaction with elastin peptides could contribute to the development of novel therapeutic strategies for COPD management.

show abstract

“…However, a minor proportion of mepolizumab was used for COPD which was not included in the label. Despite the frequent coexistence and common pathophysiology of asthma and COPD ( Maspero et al, 2022 ), previous studies have reported inconsistent results regarding the efficacy of mepolizumab for COPD ( Drick et al, 2022 ; Ohnishi et al, 2022 ). Concerning the reporter countries, Canada and America accounted for most reports.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, although mepolizumab has exhibited favorable long-term safety in clinical studies ( Gleich et al, 2021 ; Maspero et al, 2022 ), long-term safety data beyond 1 year in real-world settings are lacking. Moreover, mepolizumab has been approved recently for severe eosinophilic asthma in patients aged 6 years and older in many countries ( Drick et al, 2022 ). However, there is limited data available to evaluate the safety of mepolizumab in the pediatric population.…”

Section: Introductionmentioning

confidence: 99%

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

Li,

Wang,

Deng

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-related adverse events based on the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.Methods: A disproportionality analysis was performed to assess the safety profile of mepolizumab based on the reports from the FAERS database between October 2015 and December 2022. Demographic information, the time to onset, the safety of long-term mepolizumab exposure as well as safety in pediatric patients were also investigated.Results: A total of 736 significant preferred terms (PTs) were identified among the 13,497 mepolizumab-associated adverse events (AEs) reports collected from the FAERS database. The frequently reported AEs including dyspnea, fatigue, and headache were in line with drug instruction and previous studies. Unexpected significant AEs such as cough, malaise, and chest discomfort were also identified. Most AEs occurred within the first month after mepolizumab initiation. Pneumonia and wheezing were frequently reported in patients with long-term mepolizumab exposure as well as in the pediatric population.Conclusion: Our results were consistent with the observations in previous clinical and real-world studies. New and unexpected AE signals of mepolizumab were also identified. Close attention should be paid to the long-term safety of mepolizumab as well as safety in the pediatric population. Prospective studies are required for optimal use of mepolizumab.

show abstract

Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD

Cited by 11 publications

References 30 publications

Anti-inflammatory drug development focusing on immune mediated diseases

Anti-inflammatory drug development focusing on immune mediated diseases

Elastin-derived peptides favor type 2 innate lymphoid cells in COPD

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

Contact Info

Product

Resources

About